A leading European university identified a gene therapy for the treatment of haemoglobinopathies. Alacrita was asked to support the Principal Investigator (PI) in developing a Commercial Development Plan (CDP) to map out the opportunity and seek funding to progress the project to PoC stage.
We first held a briefing meeting with the PI to gather as much technical information about the project as possible, including status, results/data, project plans and IP. We then conducted primary and secondary research with our established industry contacts, and using Alacrita’s in-house knowledge and experience, we developed plans for further experiments to be conducted, project costs and budget required, estimated the potential market size and top-level clinical development strategy for the end product. We held a second meeting with the PI in which we reviewed and revised the draft CDP, which was then submitted to an accelerator panel for funding consideration.
Alacrita frequently supports client programs in the gene therapy space, with our expertise spanning a range of therapeutic areas and functional disciplines.